Objective:To revise the national HIV estimates and quantify the magnitude of the HIV epidemic in Ukraine at the end of 2007.Design:Internationally recommended methods—the Workbook and Spectrum—were employed to generate the estimates. This enables comparison of results with other countries using the same methodology.Methods:Estimation of the size of most at-risk populations nationally was performed using capture-recapture, multiplier and triangulation methods. HIV prevalence among most at-risk populations was estimated by linked HIV sentinel and behavioural surveillance among injecting drug users, and men who have sex with men, and unlinked sentinel surveillance among sex workers. The range of HIV prevalence and extrapolation for populations at lower risk were determined by consensus among national stakeholders. Results were reviewed by national stakeholders and endorsed by the government of Ukraine.Results:At the end of 2007, an estimated 395 000 adults (range 230 000–573 000) aged 15–49 were living with HIV in Ukraine. Adult HIV prevalence was estimated at 1.63%, which represents the highest adult HIV prevalence of any country in Europe.Conclusions:The HIV epidemic in Ukraine continues to grow at a record pace, concentrated among most at-risk populations, the majority of whom are unaware of their HIV status. The results emphasise the need to accelerate the coverage and quality of prevention programmes among most at-risk populations and their sexual partners.
BackgroundWe evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV infections among people who inject drugs (PWID) in Eastern Europe/Central Asia. We specifically considered the needle-syringe program (NSP), opioid substitution therapy (OST), HCV and HIV diagnosis, antiretroviral therapy (ART), and/or new HCV treatment (direct acting antiviral [DAA]) in Belarus, Georgia, Kazakhstan, Republic of Moldova, and Tajikistan.MethodsWe developed a deterministic dynamic compartmental model and evaluated the number of infections averted, costs, and incremental cost-effectiveness ratios (ICERs) of interventions. OST decreased frequencies of injecting by 85% and NSP needle sharing rates by 57%; ART was introduced at CD4 <350 and DAA at fibrosis stage ≥F2 at a $2370 to $23 280 cost.ResultsIncreasing NSP+OST had a high impact on transmissions (infections averted in PWID: 42% in Tajikistan to 55% in Republic of Moldova for HCV; 30% in Belarus to 61% in Kazakhstan for HIV over 20 years). Increasing NSP+OST+ART was very cost-effective in Georgia (ICER = $910/year of life saved [YLS]), and was cost-saving in Kazakhstan and Republic of Moldova. NSP+OST+ART and HIV diagnosis was very cost-effective in Tajikistan (ICER = $210/YLS). Increasing the coverage of all interventions was always the most effective strategy and was cost-effective in Belarus and Kazakhstan (ICER = $12 960 and $21 850/YLS); it became cost-effective/cost-saving in all countries when we decreased DAA costs.ConclusionIncreasing NSP+OST coverage, in addition to ART and HIV diagnosis, had a high impact on both epidemics and was very cost-effective and even cost-saving. When HCV diagnosis was improved, increased DAA averted a high number of new infections if associated with NSP+OST.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.